Financial Data and Key Metrics Changes - The company reported operating earnings growth of 21% and EPS growth of 13%, with EPS for the quarter at $2.35 [11][12] - Total company revenue was flat at nearly $55 billion, but adjusted for contract expiration, revenue increased by 19% year-over-year [12][21] - Total company gross profit dollars increased by 10%, while SG&A increased by only 4%, indicating strong cost control [12][13] Business Line Data and Key Metrics Changes - Pharmaceutical and Specialty Solutions revenue was relatively flat at $50.4 billion, but excluding customer contract expiration, revenue increased by 20% [14][15] - GNPD segment revenue increased by 2% to $3.2 billion, driven by volume growth from existing customers [16] - Other businesses reported a 13% revenue increase to $1.3 billion, with At Home Solutions growing by 12%, Optifreight Logistics by 17%, and Nuclear by 14% [18] Market Data and Key Metrics Changes - The company generated over 99% of its enterprise revenue in the U.S., with 95% of segment profit from four of its five businesses largely unaffected by tariffs [6][7] - The company expects fiscal year 2025 revenue growth of 17% to 19% and segment profit growth of 16% to 18% in its Other segment [24] Company Strategy and Development Direction - The company has invested approximately $7 billion in the U.S. over the last two years, focusing on acquisitions, domestic manufacturing, and technology [7] - The company aims to enhance patient access, affordability, and innovation in healthcare while navigating regulatory complexities [6][7] - The addition of Advanced Diabetes Supply Group is expected to be accretive to EPS and enhance the company's capabilities in diabetes care [10][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to generate sustainable long-term growth and raised fiscal year 2025 EPS guidance to a range of $8.5 to $8.15 [10][21] - The company anticipates continued strong demand and organic growth driven by favorable market trends and competitive positioning [27][29] - Management acknowledged potential challenges from tariffs but emphasized proactive measures to mitigate impacts on customers and operations [35][36] Other Important Information - The company completed the acquisition of GI Alliance and Integrated Oncology Network, which are performing as expected [9][10] - The company has delivered adjusted free cash flow of $1.2 billion year-to-date and repurchased $750 million in shares [19][20] Q&A Session Summary Question: Strong brand and specialty sales growth - Management noted broad-based strength in brand and specialty sales, driven by multiple categories and new customer onboarding [44][46] Question: Consumer weakness related to tariffs - Management indicated no significant changes in consumer behavior or prescription demand despite macroeconomic concerns [53][54] Question: Cardinal Health brand revenue and USMCA coverage - Approximately $4 billion of GNPD revenue comes from Cardinal Health brand, which is higher margin relative to national brands [59][60] Question: Tariff impact on Cardinal Health brand - The majority of the anticipated $200 to $300 million in tariff costs will be addressed through pricing adjustments, particularly for Cardinal Health brand products [64][66] Question: Margin expansion in pharma - Management attributed margin expansion to growth in specialty and brand drug sales, acquisitions, and effective cost control measures [84][86] Question: Customer onboarding and new customer wins - The onboarding of new customers is progressing well, with a reaffirmation of $10 billion in incremental new customer revenue for the year [95][96]

Q3 FY25 Earnings Cardinal Health, Inc. May 1, 2025 © 2025 Cardinal Health. All Rights Reserved. 1 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings Cautions Concerning Forward-Looking Statements Q3 Results © 2025 Cardinal Health. All Rights Reserved. 3 © 2025 Cardinal Health. All Rights Reserved. • Q3 FY25 Earnings This presentation contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These st ...

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook Exhibit 99.1 FOR IMMEDIATE RELEASE DUBLIN, Ohio, May 1, 2025 – Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion, flat to the third quarter of fiscal year 2024. Third quarter revenue increased 19% excluding the impact of the previously communicated customer contract expiration. Third quarter GAAP operating earnings increased to $730 million and GAAP diluted ear ...

Core Viewpoint - Cardinal Health, Inc. is set to report its third-quarter fiscal 2025 results, with expectations of continued strong performance driven by recent acquisitions and robust pharmaceutical demand [1][10]. Group 1: Recent Acquisitions and Strategic Growth - The acquisition of Integrated Oncology Network (ION) in December 2024 is expected to enhance Cardinal Health's oncology services through integration into its Navista practice [2]. - In November, Cardinal Health announced plans to acquire a majority stake in GI Alliance and Advanced Diabetes Supply Group, with the acquisition of GI Alliance completed in January, supporting its multi-specialty growth strategy [3]. - These acquisitions are anticipated to positively impact the Pharmaceutical and Specialty Solutions segment, although the full effects may be realized by the end of the fiscal year [4]. Group 2: Financial Performance and Estimates - For the third quarter, the Zacks Consensus Estimate for revenues is $55.03 billion, reflecting a 0.2% increase year-over-year, while the EPS estimate is $2.15, indicating a 3.4% increase from the prior year [10]. - The Pharmaceutical and Specialty Solutions segment is projected to generate revenues of $49.41 billion, down 2.4% year-over-year, influenced by customer contract expirations [6][5]. Group 3: Product Launches and Innovations - The Nuclear and Precision Health Solutions business has begun weekly production of actinium-225 (Ac-225), enhancing the availability of investigational therapeutic drug products [7]. - The launch of the Kendall SCD SmartFlow Compression System is expected to boost sales in the Global Medical Products and Distribution segment [8]. Group 4: Market Performance and Valuation - Cardinal Health's shares have increased by 8.3% over the past three months, outperforming the Medical - Dental Supplies sector and other peers [13][17]. - The company's forward 12-month price-to-earnings (P/E) ratio is 15.7X, which is below the industry average of 16.7X, indicating potential for growth relative to its peers [18][19]. Group 5: Long-Term Growth Prospects - Cardinal Health is constructing a new at-Home Solutions distribution center in Fort Worth, TX, expected to be operational by summer 2025, which will enhance its distribution capabilities [20]. - The opening of a new distribution center in Boylston, MA, is anticipated to strengthen supply chain resiliency and improve service for New England customers [21].

Group 1 - The upcoming report from Cardinal Health (CAH) is expected to show quarterly earnings of $2.15 per share, reflecting a 3.4% increase year-over-year [1] - Analysts forecast revenues of $55.03 billion for the quarter, indicating a 0.2% increase compared to the previous year [1] - The consensus EPS estimate has been revised 0.1% lower over the last 30 days, indicating a reevaluation of initial estimates by analysts [1][2] Group 2 - Analysts estimate that 'Revenue- Pharmaceutical and Specialty Solutions' will reach $50.33 billion, representing a -0.6% change from the year-ago quarter [4] - The 'Revenue- Medical Products and Distribution' is projected to be $3.21 billion, indicating a year-over-year increase of 3.2% [4] - Segment profit for 'Pharmaceutical and Specialty Solutions' is forecasted to be $635.77 million, up from $580 million in the same quarter last year [5] Group 3 - The 'Segment profit- Global Medical Products and Distribution' is expected to reach $44.16 million, compared to $20 million in the previous year [5] - Over the past month, Cardinal shares have recorded returns of +0.8%, while the Zacks S&P 500 composite has seen a -4.3% change [5] - Cardinal Health holds a Zacks Rank 3 (Hold), suggesting its performance will likely align with the overall market in the upcoming period [5]

The Zacks Medical - Dental Supplies industry in the Medical sector has a robust demand for dental services, driven by patient preferences for timely and convenient care, as well as policy initiatives aimed at enhancing access to dental health services. Dental practices witnessed heightened patient engagement over the past six months. This growth is driven by increased demand for various dental services, including cosmetic and preventive care.The pricing environment looks promising on the back of continued r ...

MELBOURNE, Australia and INDIANAPOLIS, April 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces that it has selected Cardinal Health, Inc. (NYSE:CAH, Cardinal Health)) as one of its commercial radiopharmaceutical distributors to supply finished unit doses of Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer in the United States (U.S.). Following ...

Economic Context - President Trump announced a "national economic emergency" and introduced a baseline 10% tariff on all countries to address a $1.2 trillion trade deficit, effective April 5 [1][5] - The tariffs are expected to escalate tensions and potentially lead to a global trade war, impacting market stability [8] Market Reaction - Following the announcement, Dow futures dropped over 800 points (2%), while S&P 500 futures and Nasdaq 100 futures fell by 2.7% and 3.6% respectively, indicating market apprehension [2] - Prior to the announcement, stocks had rallied as investors were optimistic about the tariffs being manageable [7] Investment Recommendations - In light of the market turmoil, it is advisable to invest in defensive sectors such as utilities, consumer staples, and healthcare [3] - Recommended stocks include: - **Southwest Gas Holdings, Inc. (SWX)**: Expected earnings growth rate of 17.1%, Zacks Rank 2, beta of 0.50, dividend yield of 3.45% [10] - **CMS Energy Corporation (CMS)**: Expected earnings growth rate of 7.8%, Zacks Rank 2, beta of 0.34, dividend yield of 2.89% [12] - **Molson Coors Beverage Company (TAP)**: Expected earnings growth rate of 6.2%, Zacks Rank 2, beta of 0.69, dividend yield of 3.07% [14] - **Sony Group Corporation (SONY)**: Expected earnings growth rate of 11.9%, Zacks Rank 1, beta of 0.94, dividend yield of 1.84% [16] - **Cardinal Health, Inc. (CAH)**: Expected earnings growth rate of 5.4%, Zacks Rank 2, beta of 0.61, dividend yield of 1.47% [18] Stock Characteristics - The recommended stocks are characterized as low-beta (beta greater than 0 but less than 1), which typically indicates lower volatility compared to the market [4]

Market Overview - Wall Street experienced volatility in Q1 2025, with U.S. stock markets expected to close negatively, contrasting with the previous two years' performances [1] - The S&P 500 and Nasdaq Composite are in negative territory year to date, while the Dow remains almost flat; small-cap and mid-cap indexes also reflect negative trends [2] Non-Tech Stock Performance - Despite the overall market downturn, several non-tech stocks have thrived, providing double-digit returns year to date [3][7] - Five recommended non-tech stocks include Tapestry Inc. (TPR), WEC Energy Group Inc. (WEC), CenterPoint Energy Inc. (CNP), CME Group Inc. (CME), and Cardinal Health Inc. (CAH), all showing favorable Zacks Rank indicating potential upside [4][8] Tapestry Inc. (TPR) - Tapestry reported robust revenue growth driven by Coach's performance and international expansion, raising its full-year revenue outlook to $6.85 billion, a 3% year-over-year growth [12] - Expected revenue and earnings growth rates for TPR are 3% and 14.5%, respectively, with a current dividend yield of 1.87% [13] WEC Energy Group Inc. (WEC) - WEC benefits from organic and inorganic asset contributions, with strategic investments aimed at strengthening infrastructure and achieving net carbon-neutral targets by 2050 [14] - Expected revenue and earnings growth rates for WEC are 9.2% and 8.5%, respectively, with a current dividend yield of 3.42% [16] CenterPoint Energy Inc. (CNP) - CenterPoint is positioned to benefit from increasing electricity demand due to the electrification of transportation and investments in renewable energy [17] - Expected revenue and earnings growth rates for CNP are 2.7% and 8%, respectively, with a current dividend yield of 2.50% [20] CME Group Inc. (CME) - CME Group's strong market position is supported by diverse derivative product lines and strategic expansions, with a focus on electronic trading and product innovation [21] - Expected revenue and earnings growth rates for CME are 4% and 3.4%, respectively, with a current dividend yield of 1.91% [23] Cardinal Health Inc. (CAH) - Cardinal Health is the second largest pharmaceutical distributor in the U.S., with its Pharmaceutical segment driving growth through various services [24] - Expected revenue and earnings growth rates for CAH are -1.9% and 5.4%, respectively, with a current dividend yield of 1.52% [26]

Core Insights - Cardinal Health's pharmaceutical segment shows resilience and growth, driven by strong demand for brand, specialty, and generic pharmaceuticals, with significant revenue contributions from GLP-1 medications and specialty distribution [1][2] - The company is strategically focusing on expanding its specialty pharmaceutical business, which is expected to capitalize on industry trends favoring high-value therapeutics [2][7] - The GMPD segment has improved significantly, with a year-over-year profit increase of approximately $240 million, indicating successful turnaround efforts [3][8] Financial Performance - Cardinal Health's shares have declined by 7.2% year-to-date, compared to a 4% decline in the industry and a 4.6% decrease in the S&P 500 Index [4] - Analysts have raised earnings estimates for fiscal years 2025 and 2026, indicating expectations of continued business improvement [10] Strategic Initiatives - The company aims to achieve a GMPD segmental profit target of $300 million by fiscal year 2026, focusing on cost containment and productivity enhancements [8] - Cardinal Health has identified opportunities to unlock at least $500 million in cash flow over the next two years through working capital improvements and business simplifications [9] Long-Term Growth Drivers - Strategic acquisitions, such as GI Alliance and ION, are expected to drive long-term growth and strengthen Cardinal Health's position in high-margin therapeutic areas [7][13] - The company's capital allocation strategy includes a $750 million share buyback commitment for fiscal 2025, balancing acquisitions and disciplined share repurchases [14] Market Challenges - Cardinal Health faces temporary revenue headwinds due to customer contract transitions, particularly the expiration of a major contract with Optum Rx [15] - Rising healthcare costs and operational expenses, especially in the GMPD segment, have pressured margins, although inflation mitigation efforts have been somewhat effective [16][17] Competitive Positioning - The company is leveraging specialty networks, logistics solutions, and supply-chain technologies to maintain a competitive edge in pharmaceutical distribution [17][18] - Despite challenges from COVID-19 vaccine-related revenue declines, Cardinal Health's diversified revenue base and focus on specialty pharmaceuticals position it for long-term stability and growth [18]